DYNAVAX TECHNOLOGIES CORP (DVAX) Stock Fundamental Analysis
USA - NASDAQ:DVAX - US2681582019 - Common Stock
10.26 USD
-0.14 (-1.35%)
10.26 USD
0 (0%)
Taking everything into account, DVAX scores 5 out of 10 in our fundamental rating. DVAX was compared to 534 industry peers in the Biotechnology industry. DVAX has only an average score on both its financial health and profitability. DVAX is growing strongly while it is still valued neutral. This is a good combination!
1. Profitability
1.1 Basic Checks
In the past year DVAX was profitable.
DVAX had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: DVAX reported negative net income in multiple years.
DVAX had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
DVAX has a Return On Assets of -5.74%. This is amongst the best in the industry. DVAX outperforms 87.27% of its industry peers.
With an excellent Return On Equity value of -10.67%, DVAX belongs to the best of the industry, outperforming 88.02% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.74% | ||
| ROE | -10.67% | ||
| ROIC | N/A |
ROA(3y)10.61%
ROA(5y)3.5%
ROE(3y)17.99%
ROE(5y)-8.35%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
In the last couple of years the Profit Margin of DVAX has declined.
The Gross Margin of DVAX (82.83%) is better than 85.96% of its industry peers.
In the last couple of years the Gross Margin of DVAX has grown nicely.
DVAX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 82.83% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-15.64%
PM growth 5YN/A
GM growth 3Y10.73%
GM growth 5Y12.85%
2. Health
2.1 Basic Checks
DVAX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for DVAX has been reduced compared to 1 year ago.
Compared to 5 years ago, DVAX has more shares outstanding
Compared to 1 year ago, DVAX has a worse debt to assets ratio.
2.2 Solvency
DVAX has an Altman-Z score of 1.42. This is a bad value and indicates that DVAX is not financially healthy and even has some risk of bankruptcy.
DVAX's Altman-Z score of 1.42 is fine compared to the rest of the industry. DVAX outperforms 63.48% of its industry peers.
The Debt to FCF ratio of DVAX is 3.95, which is a good value as it means it would take DVAX, 3.95 years of fcf income to pay off all of its debts.
DVAX's Debt to FCF ratio of 3.95 is amongst the best of the industry. DVAX outperforms 93.07% of its industry peers.
A Debt/Equity ratio of 0.53 indicates that DVAX is somewhat dependend on debt financing.
The Debt to Equity ratio of DVAX (0.53) is worse than 73.03% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | 3.95 | ||
| Altman-Z | 1.42 |
ROIC/WACCN/A
WACC8.03%
2.3 Liquidity
DVAX has a Current Ratio of 6.65. This indicates that DVAX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 6.65, DVAX is in the better half of the industry, outperforming 67.23% of the companies in the same industry.
DVAX has a Quick Ratio of 6.01. This indicates that DVAX is financially healthy and has no problem in meeting its short term obligations.
DVAX has a better Quick ratio (6.01) than 63.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.65 | ||
| Quick Ratio | 6.01 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 186.36% over the past year.
The earnings per share for DVAX have been decreasing by -19.10% on average. This is quite bad
DVAX shows a strong growth in Revenue. In the last year, the Revenue has grown by 26.67%.
DVAX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 51.10% yearly.
EPS 1Y (TTM)186.36%
EPS 3Y-19.1%
EPS 5YN/A
EPS Q2Q%75%
Revenue 1Y (TTM)26.67%
Revenue growth 3Y-14.23%
Revenue growth 5Y51.1%
Sales Q2Q%29.33%
3.2 Future
DVAX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 58.55% yearly.
Based on estimates for the next years, DVAX will show a quite strong growth in Revenue. The Revenue will grow by 15.25% on average per year.
EPS Next Y-347.92%
EPS Next 2Y65.78%
EPS Next 3Y58.55%
EPS Next 5YN/A
Revenue Next Year20.52%
Revenue Next 2Y18.53%
Revenue Next 3Y17.48%
Revenue Next 5Y15.25%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
DVAX is valuated quite expensively with a Price/Earnings ratio of 32.06.
DVAX's Price/Earnings ratio is rather cheap when compared to the industry. DVAX is cheaper than 93.63% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.10, DVAX is valued a bit more expensive.
The Price/Forward Earnings ratio is 20.74, which indicates a rather expensive current valuation of DVAX.
Compared to the rest of the industry, the Price/Forward Earnings ratio of DVAX indicates a rather cheap valuation: DVAX is cheaper than 92.70% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of DVAX to the average of the S&P500 Index (22.52), we can say DVAX is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 32.06 | ||
| Fwd PE | 20.74 |
4.2 Price Multiples
91.39% of the companies in the same industry are more expensive than DVAX, based on the Enterprise Value to EBITDA ratio.
95.88% of the companies in the same industry are more expensive than DVAX, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 18.21 | ||
| EV/EBITDA | 39.68 |
4.3 Compensation for Growth
DVAX's earnings are expected to grow with 58.55% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y65.78%
EPS Next 3Y58.55%
5. Dividend
5.1 Amount
No dividends for DVAX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
10.26
-0.14 (-1.35%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners98.07%
Inst Owner Change-0.49%
Ins Owners0.56%
Ins Owner Change-11.93%
Market Cap1.20B
Revenue(TTM)316.27M
Net Income(TTM)-52734000
Analysts80
Price Target24.48 (138.6%)
Short Float %12.19%
Short Ratio8.51
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-28.28%
Min EPS beat(2)-86.66%
Max EPS beat(2)30.1%
EPS beat(4)3
Avg EPS beat(4)-9.07%
Min EPS beat(4)-86.66%
Max EPS beat(4)30.1%
EPS beat(8)6
Avg EPS beat(8)79.21%
EPS beat(12)9
Avg EPS beat(12)63.09%
EPS beat(16)10
Avg EPS beat(16)25.23%
Revenue beat(2)1
Avg Revenue beat(2)2%
Min Revenue beat(2)-3.96%
Max Revenue beat(2)7.97%
Revenue beat(4)1
Avg Revenue beat(4)-1.56%
Min Revenue beat(4)-6.08%
Max Revenue beat(4)7.97%
Revenue beat(8)3
Avg Revenue beat(8)-0.53%
Revenue beat(12)7
Avg Revenue beat(12)3.41%
Revenue beat(16)9
Avg Revenue beat(16)9.62%
PT rev (1m)0%
PT rev (3m)0.76%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-14.09%
EPS NY rev (1m)0%
EPS NY rev (3m)-6.64%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.43%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.69%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 32.06 | ||
| Fwd PE | 20.74 | ||
| P/S | 3.8 | ||
| P/FCF | 18.21 | ||
| P/OCF | 15.78 | ||
| P/B | 2.43 | ||
| P/tB | 2.45 | ||
| EV/EBITDA | 39.68 |
EPS(TTM)0.32
EY3.12%
EPS(NY)0.49
Fwd EY4.82%
FCF(TTM)0.56
FCFY5.49%
OCF(TTM)0.65
OCFY6.34%
SpS2.7
BVpS4.21
TBVpS4.2
PEG (NY)N/A
PEG (5Y)N/A
Graham Number5.51
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.74% | ||
| ROE | -10.67% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 82.83% | ||
| FCFM | 20.89% |
ROA(3y)10.61%
ROA(5y)3.5%
ROE(3y)17.99%
ROE(5y)-8.35%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-15.64%
PM growth 5YN/A
GM growth 3Y10.73%
GM growth 5Y12.85%
F-Score5
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | 3.95 | ||
| Debt/EBITDA | 35.01 | ||
| Cap/Depr | 124.44% | ||
| Cap/Sales | 3.23% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 1023.9% | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.65 | ||
| Quick Ratio | 6.01 | ||
| Altman-Z | 1.42 |
F-Score5
WACC8.03%
ROIC/WACCN/A
Cap/Depr(3y)107.38%
Cap/Depr(5y)141.26%
Cap/Sales(3y)1.68%
Cap/Sales(5y)6.2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)186.36%
EPS 3Y-19.1%
EPS 5YN/A
EPS Q2Q%75%
EPS Next Y-347.92%
EPS Next 2Y65.78%
EPS Next 3Y58.55%
EPS Next 5YN/A
Revenue 1Y (TTM)26.67%
Revenue growth 3Y-14.23%
Revenue growth 5Y51.1%
Sales Q2Q%29.33%
Revenue Next Year20.52%
Revenue Next 2Y18.53%
Revenue Next 3Y17.48%
Revenue Next 5Y15.25%
EBIT growth 1Y94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year185.54%
EBIT Next 3Y81.5%
EBIT Next 5YN/A
FCF growth 1Y-55.18%
FCF growth 3Y-43.07%
FCF growth 5YN/A
OCF growth 1Y-49.89%
OCF growth 3Y-41.69%
OCF growth 5YN/A
DYNAVAX TECHNOLOGIES CORP / DVAX FAQ
What is the fundamental rating for DVAX stock?
ChartMill assigns a fundamental rating of 5 / 10 to DVAX.
What is the valuation status for DVAX stock?
ChartMill assigns a valuation rating of 5 / 10 to DYNAVAX TECHNOLOGIES CORP (DVAX). This can be considered as Fairly Valued.
Can you provide the profitability details for DYNAVAX TECHNOLOGIES CORP?
DYNAVAX TECHNOLOGIES CORP (DVAX) has a profitability rating of 4 / 10.
What is the expected EPS growth for DYNAVAX TECHNOLOGIES CORP (DVAX) stock?
The Earnings per Share (EPS) of DYNAVAX TECHNOLOGIES CORP (DVAX) is expected to decline by -347.92% in the next year.